Literature DB >> 24371767

Gelatinous transformation of bone marrow following the use of dasatinib in a patient with philadelphia chromosome-positive acute lymphoblastic leukemia.

Sanjeev Kumar Sharma1, Dharma Choudhary1, Anil Handoo1, Gaurav Kharya1, Nitin Gupta1, Punita Pavecha1, Ritu Chadha1.   

Abstract

Entities:  

Year:  2013        PMID： 24371767      PMCID： PMC3850372          DOI： 10.1016/j.lrr.2012.11.004

Source DB:  PubMed          Journal:  Leuk Res Rep        ISSN： 2213-0489


× No keyword cloud information.
  14 in total

1.  Gelatinous transformation of bone marrow following chemotherapy for myeloma.

Authors:  M Mathew; I Mathews; C Manohar; S Rao
Journal:  Indian J Pathol Microbiol       Date:  2001-01       Impact factor: 0.740

Review 2.  Gelatinous transformation of the bone marrow: the spectrum of underlying diseases.

Authors:  J Böhm
Journal:  Am J Surg Pathol       Date:  2000-01       Impact factor: 6.394

3.  Gelatinous transformation of bone marrow: a study of 43 cases.

Authors:  Rashmi Jain; Zeba N Singh; Nita Khurana; T Singh
Journal:  Indian J Pathol Microbiol       Date:  2005-01       Impact factor: 0.740

4.  Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.

Authors:  Frank S Hong; Catherine A Mitchell; Daniela Zantomio
Journal:  Pathology       Date:  2010-01       Impact factor: 5.306

5.  Successful management of gelatinous transformation of the bone marrow in anorexia nervosa with hematopoietic growth factors.

Authors:  Roseleen S Charania; William F Kern; Shouvik Charkrabarty; Jennifer Holter
Journal:  Int J Eat Disord       Date:  2010-06-30       Impact factor: 4.861

6.  The gelatinous bone marrow (serous atrophy) in patients with acquired immunodeficiency syndrome. Evidence of excess sulfated glycosaminoglycan.

Authors:  K Mehta; P Gascon; S Robboy
Journal:  Arch Pathol Lab Med       Date:  1992-05       Impact factor: 5.534

7.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Authors:  Craig E Daniels; Mark C Wilkes; Maryanne Edens; Ted J Kottom; Stephen J Murphy; Andrew H Limper; Edward B Leof
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

8.  Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.

Authors:  Hans Michael Kvasnicka; Juergen Thiele; Peter Staib; Annette Schmitt-Graeff; Martin Griesshammer; Jens Klose; Knut Engels; Susanne Kriener
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.

Authors:  F Fierro; T Illmer; D Jing; E Schleyer; G Ehninger; S Boxberger; M Bornhäuser
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

10.  Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: a case report.

Authors:  Prathima Prodduturi; Anamarija M Perry; Patricia Aoun; Dennis D Weisenburger; Mojtaba Akhtari
Journal:  J Oncol Pharm Pract       Date:  2012-03-07       Impact factor: 1.809
View more
  1 in total

Review 1.  Gelatinous transformation of bone marrow: rare or underdiagnosed?

Authors:  Khushdeep Kaur Shergill; Gagandeep Singh Shergill; Hari Janardanan Pillai
Journal:  Autops Case Rep       Date:  2017-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.